AUTHORS
Zainab Shahid, MBBS, Ralph Vincent Boccia, MD2, Vlady Ostrow, DO3, Amin Vakilipour4, Adriana Radu5, Amgad Shebl6, Marco Di Bacco7, Daniela Graham8, Margaret Wasilewski9, Alejandra Ramirez-Santiago10, Pedro Garbes11
AFFILIATIONS
1 Infectious Diseases Service, Memorial Sloan Kettering Cancer Center, New York, United States
2 The Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
3 CSL Behring Medical Affairs, King of Prussia, PA, United States
4 CSL Behring Clinical Development, King of Prussia, PA, United States
5 CSL Behring Clinical Development, Marburg, Germany
6 CSL Behring Clinical Development, Marburg, Germany
7 CSL Behring Global Clinical Development, Bern, Switzerland
8 CSL Behring Clinical Development, Waltham, MA, United States
9 CSL Behring Clinical Development, Waltham, MA, United States
10 CSL Behring Clinical Development, Waltham, MA, United States
11 CSL Behring Clinical Development, Waltham, MA, United States
ABSTRACT
Background: B-cell–targeting chimeric antigen receptor T-cell (CAR-T) therapies and T-cell–redirecting therapies, including T-cell engager bispecific antibody (TCE BsAb) therapies, have improved outcomes for patients with hematologic malignancies. However, these therapies frequently induce prolonged B-cell aplasia and hypogammaglobulinemia (HGG). Following CD19-directed CAR-T therapy, B-cell aplasia is an expected on-target effect, while HGG has been reported in approximately 53–100% of treated patients, depending on the population studied and timing of assessment. Prolonged B-cell depletion, B-cell aplasia, and HGG result in persistent antibody deficiency, a well-established driver of serious, recurrent, and opportunistic infections, infection-related hospitalization, and mortality. Although immunoglobulin replacement therapy (IgRT) is used in clinical practice to manage secondary immune deficiency, prospective evidence supporting subcutaneous immunoglobulin (SCIg) replacement in patients with hematologic malignancies, including those treated with CAR-T and T-cell–redirecting therapies, remains limited. Subcutaneous immune globulin (human), 20% (IgPro20/Hizentra®), a 20% SCIg preparation, is approved for IgRT in primary immunodeficiency (PID) in the US and in secondary immunodeficiency disorders in several ex-US countries, including the European Union.
Methods: IgPro20_3013 (NCT07648264) is a global Phase 3, multicenter, open-label, single-arm study evaluating the efficacy, safety, and pharmacokinetics of IgPro20 in adults with secondary immune deficiency resulting from B-cell hematologic malignancies treated with CAR-T or TCE BsAb therapies. The study plans to enroll approximately 63 participants with multiple myeloma, chronic lymphocytic leukemia, non-Hodgkin lymphoma, or B-cell acute lymphoblastic leukemia who have previously received CAR-T or TCE BsAb therapy and achieved a documented partial or complete response. This study is designed to evaluate IgPro20 in participants with secondary immune deficiency regardless of whether they are receiving ongoing IgRT at study entry, with the treatment approach tailored to their baseline immunoglobulin status. Total treatment duration is 52 weeks. The primary objective is the number of serious bacterial infections (bacteremia/sepsis, bacterial meningitis, osteomyelitis/septic arthritis, bacterial pneumonia, and visceral abscess) per participant. Secondary assessments include overall infections, safety, pharmacokinetic parameters, and treatment administration outcomes.
Results: The study has started and is actively recruiting. No efficacy, safety, pharmacokinetic, or other clinical outcome data are included in this Trial-in-Progress abstract.
Conclusions: IgPro20_3013 is designed to study the efficacy, safety, and pharmacokinetics of SCIg replacement therapy in patients with secondary immune deficiency associated with hematologic malignancies, including those treated with CAR-T and T-cell–redirecting therapies. The study will evaluate serious bacterial infection incidence, broader infection outcomes, safety, and treatment administration in this population.
DISCLOSURES
Pedro Garbes: CSL Behring - Current Employment